ProCE Banner Activity

CME

HER2-Positive Advanced Gastrointestinal Cancers: Expert Guidance on Leveraging Targeted Agents to Improve Outcomes

Video

Watch this on-demand webcast from a June 2023 symposium featuring Zev A. Wainberg, MD, PhD; Geoffrey Ku, MD; and Kanwal Raghav, MD, on evidence-based HER2 testing and the integration of modern HER2-directed therapeutics into treatment algorithms for patients with GI cancers.

Physicians: Maximum of 1.50 AMA PRA Category 1 Credits

Released: June 21, 2023

Expiration: June 20, 2024

No longer available for credit.

Share

Faculty

Geoffrey Ku

Geoffrey Ku, MD

Associate Attending Physician
Head, Esophagogastric Section, Gastrointestinal Oncology Service & member, Cellular Therapy Service
Department of Medicine

Kanwal Raghav

Kanwal Raghav, MD

Associate Professor
Gastrointestinal Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, Texas

Zev A. Wainberg

Zev A. Wainberg, MD

Professor of Medicine and Surgery
Co-Director, GI Oncology
Director, Early Phase Clinical Research Program
Jonsson Comprehensive Cancer Center
UCLA School of Medicine
Los Angeles, California

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, Daiichi Sankyo, Inc., and Seagen Inc.

AstraZeneca

Daiichi Sankyo, Inc.

Seagen Inc.

Target Audience

This program is intended for medical oncologists and other healthcare professionals involved in managing patients with GI cancers.

Program Learning Goal

This program aims to improve learners’ knowledge, confidence, competence, and performance in evidence-based HER2 testing and the integration of modern HER2-directed therapeutics into treatment algorithms for patients with GI cancers.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Integrate guideline-recommended HER2 testing in the management of patients with gastric, colorectal, and other GI cancers

  • Appraise available/emerging safety and efficacy data to appropriately identify patients with HER2-positive GI cancers that would benefit from HER2-targeted therapy

  • Evaluate the importance of biomarker testing results, the latest clinical evidence, current guideline recommendations, and relevant patient-specific, disease-specific, and treatment-specific factors to aid in the development of individualized management plans for patients with HER2-positive GI cancers

  • Implement strategies incorporating the patient and multidisciplinary care team in the effective identification and management of treatment-related adverse events related to novel therapies for HER2-positive GI cancers

  • Identify patients with HER2-positive GI cancers who are candidates for participation in clinical trials

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Geoffrey Ku, MD

Associate Attending Physician
Head, Esophagogastric Section, Gastrointestinal Oncology Service & member, Cellular Therapy Service
Department of Medicine

Geoffrey Ku, MD: researcher: Adaptimmune, AstraZeneca, Bristol-Myers Squibb, CARsgen, Daiichi Sankyo, IMAB, Merck, Oncolys, Pieris, Zymeworks; consultant/ advisor/speaker: AstraZeneca, Bristol-Myers Squibb, Daiichi Sankyo, IMAB, Merck, Pieris, Zymeworks.

Kanwal Raghav, MD

Associate Professor
Gastrointestinal Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, Texas

Kanwal Raghav, MD: consultant/advisor/speaker: AstraZeneca, Bayer, Daiichi Sankyo, Eisai, Genentech, Seattle Genetics; researcher (paid to institution): AbbVie, AstraZeneca, Bayer, Daiichi Sankyo, Eisai, Genentech, Guardant Health, Hibercell, Innovent, Janssen, Merck, Seattle Genetics, UCB Biosciences, Xencor.

Zev A. Wainberg, MD

Professor of Medicine and Surgery
Co-Director, GI Oncology
Director, Early Phase Clinical Research Program
Jonsson Comprehensive Cancer Center
UCLA School of Medicine
Los Angeles, California

Zev A. Wainberg, MD: consultant/advisor/speaker: Amgen, Arcus, AstraZeneca, Bayer, Bristol Myers Squibb, Daiichi Sankyo, Ipsen, Merck, Novartis, Pfizer, Seagen; data and safety monitoring board: Mirati.

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.5 hours. To successfully complete this activity and receive credit, learners must follow these steps during the period from June 21, 2023, through June 20, 2024:

  1. Login or Sign Up for an account by clicking at the top of this page.
  2. Read the target audience, learning objectives, and faculty disclosures.
  3. View and study the content in its entirety.
  4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.

Format

This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

 

Physician Continuing Medical Education
CCO designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.